Nicholas A.J. Botwood sold $1.2M of SNDX
Head of R&D, CMO at Syndax Pharmaceuticals Inc. 65,515 shares at an average of $18.07, traded Jun 11, 2026, filed Jun 12, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.2M at market
- +20Share of holdings soldSold 69% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-269694, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | MOption exercise Common Stock10b5-1 | +22,515 | $13.82 | $311k | 95,165 | Jun 12, 2026 |
| Jun 11, 2026 | SOpen-market sale Common Stock10b5-1 | -34,280 | $18.00 | $617k | 60,885 | Jun 12, 2026 |
| Jun 12, 2026 | MOption exercise Common Stock10b5-1 | +31,235 | $13.82 | $432k | 92,120 | Jun 12, 2026 |
| Jun 12, 2026 | SOpen-market sale Common Stock10b5-1 | -31,235 | $18.14 | $567k | 60,885 | Jun 12, 2026 |
| Jun 11, 2026 | MOption exercise Stock options (Right to buy)derivative10b5-1 | +22,515 | $0.00 | $0 | 0 | Jun 12, 2026 |
| Jun 12, 2026 | MOption exercise Stock options (Right to buy)derivative10b5-1 | +31,235 | $0.00 | $0 | 0 | Jun 12, 2026 |
Related signals
Other insiders at Syndax Pharmaceuticals Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $785k 32,375 shares | -6% | |
| 37Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $22k 1,177 shares | -1% | |
| 51Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $130k 6,847 shares | -1% | |
| 38Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $72k 3,410 shares | -2% | |
| 48Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $361k 17,159 shares | -3% | |
| 36Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $43k 2,082 shares | -1% | |
| 44Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $153k 7,412 shares | -1% | |
| 25Weak | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $2.6M 157,307 shares | -34% | |
| 13Weak | Syndax Pharmaceuticals Inc | Dennis Podlesak director | $875k 57,600 shares | -27% | |
| 30Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $12k 1,296 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.